The Endurance Trial is a phase IV open label clinical study to assess the need for ongoing
intravitreal aflibercept injections after the 3-year VISTA DME (VGFT-OD-1009) end-point.
Subjects will be treated with intravitreal aflibercept injections pro re nata (PRN) based on
the presence of CR-DME (Clinically Relevant-Diabetic Macular Edema). In addition, subjects
who meet re-treatment criteria will be eligible for focal laser treatment every 90 days.
Phase:
Phase 4
Details
Lead Sponsor:
Northern California Retina Vitreous Associates Palmetto Retina Center, LLC